Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1653 - Pharmacokinetics (PK) of the pan-FGFR inhibitor erdafitinib in urothelial carcinoma


09 Oct 2016


Poster display


Josep Tabernero


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


J. Tabernero1, J.R. Infante2, A. Mita3, C. Keung4, D. Skee4, H. Xie5, T. Parekh6, P. De Porre7, F.R. Luo8, J. Soria9

Author affiliations

  • 1 Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 2 Drug Development Program, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville/US
  • 3 Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, CA 90048 - Los Angeles/US
  • 4 Clinical Pharmacology, Janssen Research and Development, Raritan/US
  • 5 Experimental Medicine, Janssen Research and Development, Spring House/US
  • 6 Cdtl Oncology, Janssen Research and Development, Raritan/US
  • 7 Clinical Oncology, Janssen Research and Development, Beerse/BE
  • 8 Experimental Medicine, Janssen Research and Development, Raritan/US
  • 9 Department Of Medicine Ditep, Gustave Roussy Cancer Campus and University Paris-Sud, 94805 - Villejuif/FR


Abstract 1653


Erdafitinib (JNJ-42756493) potently inhibits cell proliferation in FGFR pathway-activated cancer cell lines. The targeted therapeutic range for unbound plasma erdafitinib is >0.5 to 2.4 ng/mL based on efficacious concentrations in preclinical tumor models. This analysis examined the PK of erdafitinib in the targeted population of patients with urothelial carcinoma and FGFR aberrations.


The first-in-human, open-label, multicenter, phase 1 study included patients with advanced or refractory solid tumors or lymphoma and FGFR aberrations. Patients received erdafitinib 0.5–12 mg once daily (QD) continuously (C) or erdafitinib 10 or 12 mg 7d on/7d off intermittently (I) in 28d cycles. A phosphate binder (sevelamer) could be used to manage elevated phosphate. This analysis focused on PK for 9 mg C, 10 mg I, and 12 mg I. Blood samples for PK were obtained at steady state on Cycle 1 Day 8 (9 mg C) or Cycle 1 Day 7 (10 or 12 mg I) and analyzed for total erdafitinib, of which ∼0.3% is unbound.


Among 28 patients with urothelial carcinoma, 5 received erdafitinib 9 mg C, 10 mg I, or 12 mg I and provided extensive PK samples at steady state. Maximum concentration (Cmax) for total erdafitinib was 1,130 to 2,690 ng/mL and area under the 24-hour concentration-time curve (AUC24h) was 19,900 to 52,600 ng•h/mL. Phosphate concentration, a pharmacodynamics biomarker, increased when erdafitinib concentrations increased and returned toward baseline when erdafitinib was stopped. Among patients with any tumor type and PK data at steady state, total drug concentrations were similar with or without concurrent sevelamer use (Table). Anti-tumor efficacy and safety are reported separately.

Total Erdafitinib Concentrations* at Steady State by Sevelamer Use - Any Tumor Type, Mean (Coefficient of Variance %)

Dose N Cmax, ng/mL AUC24, ng•h/mL
9 mg continuous (without sevelamer) 6 1,140 (44.8) 21,900 (44.8)
10 mg intermittent 15
With sevelamer 11 1,850 (34.7) 34,300 (50.6)
Without sevelamer 4 1,520 (25.1) 31,500 (30.4)
12 mg intermittent 14
With sevelamer 9 1,950 (60.6) 34,000 (50.2)
Without sevelamer 5 2,160 (60.2) 31,900 (115.7)

* Approximately 0.3% of total erdafitinib is unbound in plasma.


Exposure for the pan-FGFR inhibitor erdafitinib at 9 mg C, 10mg I, and 12 mg I achieved or exceeded the targeted therapeutic range in patients with urothelial carcinoma and FGFR aberrations. Concurrent use of a phosphate binder did not affect erdafitinib PK.

Clinical trial identification


Legal entity responsible for the study

Janssen Research & Development, LLC


Janssen Research & Development, LLC


J. Tabernero: Consultant/Advisory role: Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Lilly, MSD, Merck Serono, Novartis, Roche, Sanofi, Symphogen, Takeda and Taiho. A. Mita: Speakers' Bureau: Genentech. C. Keung, D. Skee, H. Xie, T. Parekh, P. De Porre, F.R. Luo: Employee of Janssen Research & Development and Johnson & Johnson stock holder. J-C. Soria: Honoraria: Johnson and Johnson. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings